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ABSTRACT
Background: High fructose intake causes hepatic insulin resistance
and increases postprandial blood glucose, lactate, triglyceride,
and uric acid concentrations. Uric acid may contribute to in-
sulin resistance and dyslipidemia in the general population. In
patients with hereditary fructose intolerance, fructose consumption
is associated with acute hypoglycemia, renal tubular acidosis, and
hyperuricemia.
Objective: We investigated whether asymptomatic carriers for
hereditary fructose intolerance (HFI) would have a higher sensitivity
to adverse effects of fructose than would the general population.
Design: Eight subjects heterozygous for HFI (hHFI; 4 men, 4
women) and 8 control subjects received a low-fructose diet for
7 d and on the eighth day ingested a test meal, calculated to
provide 25% of the basal energy requirement, containing 13C-labeled
fructose (0.35 g/kg), glucose (0.35 g/kg), protein (0.21 g/kg), and
lipid (0.22 g/kg). Glucose rate of appearance (GRa, calculated with
[6,6-2H2]glucose), fructose, net carbohydrate, and lipid oxidation,
and plasma triglyceride, uric acid, and lactate concentrations were
monitored over 6 h postprandially.
Results: Postprandial GRa, fructose, net carbohydrate, and lipid
oxidation, and plasma lactate and triglyceride concentrations were
not significantly different between the 2 groups. Postprandial plasma
uric acid increased by 7.2% compared with fasting values in hHFI
subjects (P < 0.01), but not in control subjects (−1.1%, ns).
Conclusions: Heterozygous carriers of hereditary fructose in-
tolerance had no significant alteration of postprandial fructose
metabolism compared with control subjects. They did, however,
show a postprandial increase in plasma uric acid concentration
that was not observed in control subjects in responses to ingestion
of a modest amount of fructose. This trial was registered at the
US Clinical Trials Registry as NCT02979106. Am J Clin Nutr
2018;108:1–8.
Keywords: fructose, hereditary fructose intolerance, uric acid,
plasma triglyceride concentration
INTRODUCTION
There is increasing concern that a high fructose intake may
be directly involved in the development of obesity, diabetes
mellitus, dyslipidemia, gout, and high blood pressure (1, 2).
This proposal is mainly supported by animal studies (3), but
there are nonetheless robust observations in humans that fructose
overfeeding impairs hepatic insulin sensitivity, increases de
novo lipogenesis and VLDL secretion, and causes hypertriglyc-
eridemia and ectopic lipid deposition in the liver and skeletal
muscle (4–7). Sucrose and high fructose corn syrup, which
both contain nearly isomolar amounts of glucose and fructose,
are the major sources of dietary fructose. Concerns about the
health effects of these sugars have recently led several health
organizations to propose that consumption of free sugars should
not exceed 5% (8) or 10% (9) of total energy intake (10, 11).
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A high fructose intake also increases blood lactate and uric
acid concentrations (12, 13). The latter is often increased in
patients with metabolic syndrome, and has been previously
proposed as one of its diagnostic criteria (14). Fructose-induced
hepatic phosphate depletion, leading to defective ATP recycling,
increased ATP hydrolysis up to adenosine, and enhanced purine
degradation, is often proposed as the main factor responsible
for increased uric acid production (15). Recently it has been
proposed that hyperuricemia may be not only a consequence
of fructose metabolism, but also a key mediator in some of the
adverse cardiometabolic effects of fructose (16–18). However,
the underlying mechanisms remain incompletely elucidated (19).
It has been proposed that uric acid may contribute to insulin
resistance by impairing endothelium-dependent vasodilation
(16), promoting proinflammatory effects (17) and dyslipidemia
by activating de novo lipogenesis (18).
These consequences of fructose overconsumption may be
even more marked in individuals with hereditary alterations
in fructose metabolism. Indeed, individuals with hereditary
fructose intolerance (HFI), owing to biallelic mutations in the
gene coding for aldolase B (ALDOB), may develop acute,
life-threatening manifestations when exposed to even minute
amounts of fructose. In such individuals, administration of
small amounts of fructose (or sorbitol, which is a precursor for
endogenous fructose synthesis) will cause acute ATP depletion
in hepatocytes and proximal kidney tubule cells owing to rapid
phosphorylation of fructose by fructokinase and accumulation
of intracellular fructose-1-phosphate. The energy crisis thus
elicited is responsible for acute hypoglycemia, renal tubular
acidosis, and hyperuricemia (20–25). Chronic consumption of
small amounts of fructose also causes fatty liver and renal tubular
dysfunction in HFI individuals (26). No genotype-phenotype
correlations have been identified for HFI; clinical severity and
extent of organ damage appear to depend on individual nutritional
habits. HFI prevalence in central Europe is estimated to be
1:26,100 (27). Heterozygous carriers of the ALDOB mutation
are therefore quite common in the general population, with
a predicted frequency ranging between 1:55 and 1:120 (28).
Few studies have examined the effect of fructose ingestion in
subjects heterozygous for HFI (hHFI). Heterozygous carriers are
generally considered to have normal fructose metabolism since a
∼50% level of ALDOB activity is presumed to be sufficient for
adequate function. In contradiction with this postulate, however,
heterozygous carriers were reported to have enhanced uric acid
responses to large intravenous and/or oral fructose loads (29, 30).
We therefore hypothesized that heterozygous carriers may also
have mild defects of fructose metabolism and/or a larger increase
in cardiometabolic risk factors than the normal population after
ingestion of moderate amounts of fructose.
METHODS
Subjects
Eight hHFI subjects (4 men, 4 women) and 8 control subjects
(4 men, 4 women) were included in the study. The hHFI subjects
were parents of children with HFI followed in the Department
of Medical Genetics at the University Hospital of Liège/CHU
Sart Tilman, Liège. The ALDOB genotype was established
in heterozygous subjects as a part of the routine assessment
and follow-up, and for genetic counseling purposes. Control
FIGURE 1 Experimental setting of the metabolic test. Each subject was
studied on one occasion, after 7 d on a low-fructose diet (<10 g/d). On day
8, overnight fasted subjects remained on a bed to assess their postprandial
response to a mixed meal (0.35 g glucose/kg, 0.35 g fructose/kg, 0.21 g
protein/kg, and 0.22 g lipid/kg). Dietary fructose was labeled with 1% [U-
13C6] fructose, and plasma glucose metabolism was measured with [6,6-
2H2]glucose. An indirect calorimetry period and baseline plasma samples
were obtained prior to meal ingestion, and repeated sequentially thereafter
(for details, see Methods). T, time point.
subjects were recruited in the general population and were
genotyped in the Center for Molecular Diseases (Switzerland)
to ensure that they had no ALDOB mutation. The subjects were
currently not taking any medication, and had no history of
diabetes, dyslipidemia, or renal insufficiency. Before inclusion,
they underwent a physical examination to ensure that they were
in good physical health. The experimental protocol was approved
by the Ethics Committee of the University Hospital of Liège
(Belgium) and Lausanne (Switzerland). All participants provided
written informed consent. This trial was registered at the US
Clinical Trials Registry as NCT02979106.
Study design
Each subject was studied on a single occasion of 8 d. During
the first 7 d, the subjects were asked to consume a low-fructose
diet (<10 g/d, counseled by a registered dietitian). The subjects
then reported to the Clinical Research Center on day 8 for a
metabolic test in which the response to a fructose-containing
mixed meal was assessed (Figure 1).
Metabolic test
On day 8, subjects reported to the Clinical Research Center of
CHU Sart Tilman, Liège at 0700 after a 12-h fast. Upon their
arrival, their weight was recorded and their body composition
was measured using bioelectrical impedance analysis (Imp Df50,
ImpediMed). The subjects were asked to empty their bladder, and
the urine passed was discarded. Urine was thereafter collected
from 0800 (t = 0 min) to the end of the test at 1600 (t =
480 min). After subjects had been transferred to a bed, a catheter
was inserted into a vein of the right forearm for blood sampling.
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Patency was maintained by a slow infusion of 0.9% NaCl
(150 mL over 6 h). No additional drink was allowed during the
test. Another catheter was inserted into a vein of the left arm and
was used for the administration of a primed continuous infusion
of [6,6-2H2]glucose [bolus, 2 mg/kg body weight (BW), and
continuous infusion, 0.03 mg · kg BW–1 · min–1; Cambridge
Isotope Laboratories] throughout the test. Subjects were studied
for 6 h after the ingestion of a controlled-weight maintenance
meal containing (means ± SDs) 0.35 ± 0.02 g fructose/kg BW
(labeled with 1% [U-13C6]fructose), 0.35 ± 0.02 g glucose/kg
BW, 0.21± 0.01 g protein/kg BW and 0.22± 0.03 g lipid/kg BW.
This meal was calculated to provide 25% of resting 24-h energy
requirements, calculated by using the Harris-Benedict equation
and a correction factor of 1.1 to account for dietary thermogenesis
(31). Blood and breath samples were collected at baseline
(t = baseline), immediately after catheter insertion, before the
test meal (t = 0 min), and every 30 min after the test meal until
t = 360 min. Blood pressure was measured at baseline using an
automatic blood pressure device (Omron 907, Omron). Energy
expenditure and net substrate oxidation rates were monitored for
90 min under fasting conditions (baseline; t = −90 min to t = 0
min) and for 180 min after ingestion of the test meal at 2 separate
times (t = 90 min to t = 180 min) and t = 270 min to t = 360
min) by indirect calorimetry (Deltatrac II, Datex Instrument).
Analytic procedures
Appropriate informed consent for genetic testing was obtained
from all individuals. Blood samples were collected on EDTA and
genomic DNA was extracted from blood leukocytes according to
standard protocols. The 8 coding exons of theALDOB gene (Gen-
Bank accession NM_000035.3, Ensembl ENST00000374855),
as well as the intron-exon boundaries, were amplified from
genomic DNA by polymerase chain reaction (using the Qiagen
TaqPCR MasterMix, and ALDOB specific primers—avalaible
upon request) and directly sequenced by Sanger sequencing on
a ABI3500 sequencer according to the manufacturer’s procedure
(Applied Biosystems/LifeTechnologies).
Plasma [6,6-2H2]glucose isotopic enrichment and plasma
and urinary fructose concentrations were measured by gas
chromatography-mass spectrometry (GC-MS). Plasma [6,6-
2H2]glucose enrichment was measured on pentaacetyl deriva-
tives, using GC-MS in chemical ionization mode with selective
monitoring of m/z 333 and m/z 331 as described previously
(32). After the addition of 69 nmol D-[1,2,3-13C3]fructose as
an internal standard, 250-µL plasma samples were deproteinized
by ZnSO4-Ba(OH)2, partially purified over anion- and cation-
exchange resins, dried, and derivatized with acetic anhydride and
pyridine. Samples were then dried under a stream of nitrogen
and resuspended in 60 μL of ethyl acetate. To 250 μL of urine,
23 nmol of internal standard solution (D-[1,2,3-13C3]fructose)
and 55 μL of urease (26 units/mL, recombinant from Canavalia
ensiformis; jack bean, Sigma) were vortex-mixed and centrifuged
for 10 min at 14,000 × g and incubated for 60 min at 37°C. Then
800 µL of cold methanol was added, and the samples were again
vortex-mixed and centrifuged. Next, 500 μL of the supernatant
was transferred into a glass vial and dried under reduced pressure.
Urinary samples were then derivatized and analyzed as described
previously (33). Plasma and urinary fructose were analyzed
by GC-MS (Agilent Technologies) in electron impact mode,
with selected monitoring of m/z 275 and m/z 277. The fructose
concentration in samples was determined from the ratio of m/z
277 to m/z 275 by means of an unlabeled pure fructose standard
curve. After deproteinization with sulfosalicylic acid, plasma
amino acids were separated and quantified by ion exchange
chromatographywith post-column ninhydrin derivatization using
a JLC-500/V AminoTac amino acid analyzer (Jeol Ltd).
Plasma glucose, lactate, triglyceride, total cholesterol, HDL
cholesterol, LDL cholesterol, uric acid, creatinine (Crt), nones-
terified fatty acids (NEFAs), urea and urinary urea were measured
using enzymatic methods (RX Monza analyser, Randox Lab-
oratories Ltd). Commercial radioimmunoassay kits were used
for the determination of plasma insulin and glucagon. Creatine
(Cr) and guanidinoacetate (GAA) determination in plasma
was performed by liquid chromatography/MS-MS, as described
elsewhere (34). Briefly, D3-Cr and [13C2]GAA (CDN Isotopes)
were added to plasma samples as internal standards, and Cr and
GAA were purified by microsolid phase extraction (Oasis MCX
μElution Plate, Waters). Separation of Cr and GAAwas achieved
on an ACQUITY UPLC BEH HILIC silica column (Waters)
using an H2O-acetonitrile gradient. The column effluent was
monitored using a Triple Quadrupole TSQ Quantum Discovery
(Thermofisher) equipped with an electrospray interface. Samples
were analyzed in positive ionization mode using the selected
reaction monitoring mode.
Calculations
Plasma glucose rate of appearance (GRa) and disposal were
calculated from glucose concentration and [6,6-2H2]glucose
isotopic enrichment using the nonsteady state equation of Steele
as modified by DeBodo et al. (35), using a volume of distribution
for glucose of 0.2 times BW and a pool fraction of 0.75.
[13C]Fructose oxidation (FOX) was calculated over 30 min
periods as:
FOX = (180 ×13 CO2 IE ×VCO2)/
(13C-fructose IE(meal) × 22.29 × 6 × 0.8)(g/min)
(1)
where 13CO2 IE is breath CO2 isotopic enrichment (atom%
excess),VCO2 is carbon dioxide production in the breath (L/min),
[13C]fructose IE(meal) is the amount of 13C-labeled fructose in the
meal (mol% excess), 180 is the molecular weight of fructose,
22.29 is the volume occupied by 1 mol of CO2 under laboratory
conditions (L), 6 is the number of carbons in a fructose molecule
and 0.8 is the recovery factor of 13CO2 in breath (36).
The area under the FOX curvewas then calculated to determine
the total fructose oxidation over 6 h (grams), and the nonoxidative
fructose disposal (grams) was obtained by subtracting the total
FOX from the fructose load (grams). Similarly, net glycogen
synthesis was obtained by subtracting the total carbohydrate
oxidation (accounting for the net oxidation of endogenous and
exogenous carbohydrates) from the glucose and fructose intake
(grams).
The fractional excretion (Fe) of sodium (Fe-Na) was calculated
as:
Fe-Na (%) = ([(PCr ∗ UNa) / (PNa ∗ UCr)]) × 100 (2)
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where PCrt = plasma Crt (µmol/L), UNa = urinary sodium
(µmol/L), PNa = plasma sodium (µmol/L) and UCrt = urinary
Crt (µmol/L). A similar calculation was done to calculate the
fractional excretion of urea (Fe–Urea) and of uric acid (Fe–Uric
acid).
Crt clearance (CLCrt) was measured directly by collecting a
6-h urine sample and then drawing a blood sample, and was
calculated as:
CLCrt = (UCrt × Vol/Time)/(PCrt/1000) (3)
where UCrt = urine Crt (µmol/L), Vol = volume collected (mL),
time = collection time (min) and PCrt = plasma Crt (µmol/L).
Statistics
Based on previous data obtained in our laboratory with
similar methodology (37), we calculated that a sample size of
8 subjects/group would be appropriate (1 – β: 80%; α = 0.05)
to detect an ∼20% difference in mean GRa between hHFI and
control subjects after fructose loading. First, all the variables
(expressed as mean ± SD) were visually inspected, then
distribution normality and homoscedasticity were assessed with
the use of Shapiro-Wilk and Bartlett’s tests, and data were
log-transformed when appropriate (plasma insulin, uric acid,
ornithine and citrulline). Baseline patients’ characteristics, mean
GRa, and carbohydrate and lipid oxidations were determined
using an unpaired Student’s t test. The significance of changes
over time was determined by mixed-models analysis, with fixed
effects of time (T) and condition (C), and random effects for
subject-specific intercepts and slopes. The time and condition
interaction (T × C) and baseline (B) effects were included in
the models each time that model goodness of fit was improved.
Linear regression was checked using Pearson’s coefficient.
Analyses were performed with R, version 3.0.3, and the level of
significance was set as 2-tailed P = 0.05.
RESULTS
Subjects’ characteristics and mutation analysis
At inclusion, control and hHFI subjects did not differ in age,
weight, BMI, percentage of body fat, blood pressure, or heart
rate (Table 1). Absence of mutation in the ALDOB (OMIM
#229,600) coding sequence was confirmed in control subjects
(n= 8). Heterozygosity for themost common pathogenic variants
in the ALDOB gene was identified in the 8 hHFI subjects
(c.448G > C, p.Ala150Pro; ExAC frequency 0.2% in 7 subjects
and the c.548T > C, p.Leu183Pro pathogenic variant in one
subject).
Carbohydrate and lipid metabolisms
Baseline GRa, net carbohydrate and lipid oxidation, plasma
carbohydrate, lipids and hormone concentrations were not
different in fasted hHFI and control subjects (all P > 0.05).
GRa increased during the first 120 min after meal ingestion,
then returned to fasting values, similarly in both hHFI and
control subjects (kinetic data not shown; T effect: P < 0.05;
T × C effect: P > 0.05). Energy expenditure and carbohydrate
oxidation increased, and lipid oxidation decreased, in both groups
TABLE 1
Baseline clinical characterization of study subjects1
Characteristics Control subjects hHFI subjects
Age, y 37.25 ± 5.12 36.38 ± 6.70
Weight, kg 73.51 ± 16.66 74.36 ± 18.21
BMI, kg/m2 24.32 ± 3.84 24.92 ± 4.39
Body fat, % 23.50 ± 4.84 28.14 ± 6.53
Lean body mass, % 76.38 ± 4.84 71.89 ± 6.50
Systolic BP, mm Hg 121.46 ± 15.93 121.56 ± 16.07
Diastolic BP, mm Hg 75.34 ± 9.08 75.64 ± 10.43
Heart rate, beats/min 63.13 ± 8.75 63.14 ± 11.11
1Values presented as means ± SDs (n = 8 subjects/group). Distribution
normality and homoscedasticity were visually inspected and checked using
Shapiro-Wilk and Bartlett’s tests. Changes were assessed by a Student’s
unpaired t test. Control and hHFI subjects showed no significant difference
in anthropometric variables (all P > 0.05). BP, blood pressure; hHFI,
heterozygous for hereditary fructose intolerance.
(all T effects: P < 0.05; all T × C effects: P > 0.05). Over
the 6 h following the test meal, 36.8% ± 4.05% (9.4 ± 1.9
g/6 h) and 38.8%± 6.0% (9.5± 2.0 g/6 h) of the ingested fructose
were oxidized to CO2 in control and hHFI subjects, respectively
(P > 0.05). The remaining 63.2% ± 4.1% (16.2 ± 3.4 g) and
61.2% ± 6.0% (15.2 ± 4.1 g) were disposed of nonoxidatively
(P> 0.05). Net glycogen synthesis was also not different between
control and hHFI subjects (23.7± 15.0 compared with 17.9± 5.1
g; P = 0.32) (Table 2).
After ingestion of the fructose-containing mixed meal, sys-
temic fructose concentration increased to a peak of between
200 and 250 µmol/L after 60 min, then decreased similarly in
hHFI and control subjects (Figure 2A; T effect: P < 0.01; T
× C effect: P = 0.60). Plasma lactate, glucose, and insulin
concentrations followed similar postprandial patterns, with no
difference between conditions (Figure 2B–D; all T effects:
P < 0.05; all T × C effects: P > 0.05). Plasma glucagon was
not significantly altered by meal ingestion (data not shown; all
P > 0.05). NEFA concentrations decreased (Figure 2E; T effect:
P < 0.01; T × C effect: P = 0.35) and total triglycerides
concentrations increased over time (Figure 2F; T effect:P< 0.01;
TABLE 2
Substrate kinetics over 6 h after ingestion of a fructose-containing mixed
meal in hHFI and control subjects1
Characteristics Control subjects hHFI subjects
Fructose intake, g 25.6 ± 5.0 24.7 ± 5.2
FOX, g/6 h 9.4 ± 1.9 9.5 ± 2.0
NOFD, g/6 h 16.2 ± 3.4 15.2 ± 4.1
Total carbohydrate oxidation, g/6 h 27.6 ± 13.0 31.5 ± 10.7
Net glycogen synthesis, g/6 h 23.7 ± 15.0 17.9 ± 5.1
GRa, mg · kg–1 · min–1 2.2 ± 0.2 2.4 ± 0.2
Lipids oxidation, g/6 h 22.9 ± 6.9 20.5 ± 6.1
Protein oxidation, g/6 h 16.6 ± 6.4 19.7 ± 7.0
Energy expenditure, kcal/6 h 383.0 ± 77.9 389.4 ± 67.7
1Values presented as means ± SDs (n = 8 subjects/group). Distribution
normality and homoscedasticity were visually inspected and checked using
Shapiro-Wilk and Bartlett’s tests. Changes were assessed by a Student’s
unpaired t test. Control and hHFI subjects showed no significant difference
in substrate kinetics (all P > 0.05). FOX, fructose oxidation; GRa, glucose
rate of appearance; hHFI, heterozygous for hereditary fructose intolerance;
NOFD, nonoxidative fructose disposal.
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FIGURE 2 Plasma substrates and insulin concentrations over 6 h after ingestion of a fructose-containing mixed meal in hHFI and control subjects. Changes
over time in plasma fructose (A), lactate (B), glucose (C), insulin (D), NEFA (E), and TG (F) concentrations after ingestion of a fructose-containing mixed
meal (time = 0 min). Values are means ± SDs (n = 8 subjects/group). Distribution normality and homoscedasticity were visually inspected and checked using
Shapiro-Wilk and Bartlett’s tests. Insulin values were log-transformed for analyses. Changes over time were assessed by mixed-model analysis, with time and
condition as fixed effects. The T × C interaction and baseline values were included as covariates each time that model goodness of fit was improved. Time-
paired contrasts were used to determine differences between conditions. There was no significant difference between conditions over time (T × C interaction:
all P > 0.05). hHFI, heterozygous for hereditary fructose intolerance; NEFA, nonesterified fatty acids; T × C, time-by-condition; TG, triglycerides.
T × C effect: P = 0.48) similarly in hHFI and control subjects.
Total- and LDL-cholesterol concentrationswere also not different
between the 2 groups (data not shown; all P > 0.05).
Blood and urinary uric acid, creatinine, amino acids, and
related metabolites
Baseline plasma uric acid (P = 0.43) and urea (P = 0.36)
concentrations and urinary indexes (Supplemental Table 1;
all P > 0.05) were highly variable among subjects and were
similar in hHFI and control subjects. Interestingly, the plasma
Crt concentration was significantly lower (P = 0.04), whereas
the plasma glycine was higher (P = 0.04) and arginine tended
to be higher (P = 0.06), in fasted hHFI subjects compared with
control subjects. Other amino acids measured in the fasted state
did not differ between groups (Supplemental Table 2). Plasma
Cr (38.1± 13.5 compared with 29.5± 9.9 µmol/L; P> 0.05) and
guanidinoacetate (2.3 ± 0.3 compared with 2.1 ± 0.6 µmol/L;
P > 0.05) also showed no statistical difference at baseline (data
not shown; all P > 0.05).
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FIGURE3 Plasma urea, uric acid, and Crt concentrations over 6 h after ingestion of a fructose-containingmixedmeal in hHFI and control subjects. Changes
over time in plasma urea (A), uric acid (B), and Crt (C) concentrations after ingestion of a fructose-containing mixed meal (time = 0 min), and urea:Crt ratio
(D). Values are means ± SDs (n = 8 subjects/group). Distribution normality and homoscedasticity were visually inspected and checked using Shapiro-Wilk
and Bartlett’s tests. Uric acid values were log-transformed for analyses. Changes over time were assessed by mixed-model analysis, with time and condition as
fixed effects. The T × C interaction and baseline values were included as covariates each time that model goodness of fit was improved. Time-paired contrasts
were used to determine differences between conditions. The linear relation between covariates was determined using Pearson’s test (coefficients indicated).
Plasma urea and uric acid were not different at baseline (both P > 0.05), but were subsequently significantly higher in hHFI subjects than in control subjects
(both T × C interaction: P < 0.05). Plasma creatinine was lower at baseline in hHFI subjects than in control subjects (P = 0.04), but then evolved similarly
in both conditions (T × C interaction effect: P = 0.25; baseline effect: P < 0.01). Plasma urea:Crt ratio was higher at baseline and after fructose ingestion. ∗,
hHFI and control subjects significantly different (P < 0.05). Crt, creatinine; hHFI, heterozygous for hereditary fructose intolerance; NEFA, nonesterified fatty
acids; T × C, time-by-condition; TG, triglycerides.
Postprandial plasma uric acid increased significantly above
fasting concentrations in hHFI subjects but not in control
subjects (Figure 3B: T effect: P = 0.29; T × C effect:
P = 0.03). The average increase was +7.2% of preprandial
hHFI values (P < 0.01) compared with −1.1% in control
subjects (P = 0.16). Ingestion of the mixed meal decreased
plasma urea concentrations only in control subjects (Figure 3A:
T effect: P < 0.01; T × C effect: P < 0.01). No effect on Crt
concentrations was shown (Figure 3C: T effect: P = 0.13; T × C
effect: P = 0.25). However, the urea:Crt ratio was significantly
higher in hHFI subjects in both plasma (Figure 3D: T effect:
P < 0.01; T × C effect: P < 0.01) and urine (data not shown;
P < 0.05). There was no statistical difference between hHFI
and control subjects for postprandial plasma and urinary amino
acids (Supplemental Table 2; all T × C effects: P > 0.05) or
Crt and GAA concentrations (data not shown; all T × C effects:
P > 0.05). There was no significant change in urinary indexes
(Supplemental Table 1).
DISCUSSION
Given the high dietary intake of fructose in many affluent
countries and North American populations (38), as well as the
recognition that fructose may be associated with specific adverse
metabolic effects such as dyslipidemia, hepatic steatosis, and
hepatic insulin resistance, we wondered whether the possibly
deleterious effects of dietary fructose may be enhanced in
hHFI individuals compared with the general population. To our
knowledge, this study provides the first detailed assessment
of postprandial responses to a mixed meal containing fructose
in carriers of one mutated ALDOB allele. A relatively small
fructose load (∼25 g) was chosen to replicate levels of
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fructose intake commonly observed in the general population.
In addition, fructose was incorporated into a liquid mixed meal
together with isocaloric amounts of glucose in order to obtain
a fructose:glucose ratio comparable to that of sucrose or high
fructose corn syrup (39).
We had hypothesized that, compared with control counter-
parts, hHFI subjects would present an increased sensitivity to
fructose-induced metabolic alterations, leading to dysregulation
of glucose and lipid homeostasis. Postprandial systemic GRa
was selected as our primary outcome since this variable provides
a reliable estimate of overall postprandial glucose homeostasis.
However, GRa measured after ingestion of a fructose-containing
meal was not different in hHFI and control subjects. We also
monitored fructose metabolism with the use of 13C-labeled
fructose, and observed that fructose oxidation and nonoxidative
fructose disposal were not different in hHFI and control subjects.
This observation is consistent with previous reports that hHFI
subjects have normal splanchnic fructose uptake unless the dose
administered is very high (40, 41). We next turned our attention
to markers of postprandial glucose and lipid homeostasis. There
was no difference in postprandial net carbohydrate oxidation,
nor in blood glucose and triglyceride concentrations. Our results
therefore do not support the hypothesis that hHFI subjects may
be more prone to fructose-induced dysregulation of glucose
homeostasis than the general population, at least with moderate
(25 g) fructose loads.
However, an analysis of exploratory outcomes suggested that
hHFI subjects may have an increased sensitivity to fructose-
induced hyperuricemia. Ingestion of the fructose-containingmeal
increased significantly plasma uric acid concentrations in hHFI
subjects, but had no such effect in control subjects. Over 30 y
ago, Oberhaensli et al. (29) had already reported an enhanced uric
acid response to a 50-g fructose load in hHFI subjects, and had
suggested that heterozygous carriers of ALDOB mutations may
be at increased risk of gout. The uric acid concentrations we ob-
served were markedly lower than those reported by Oberhaensli
et al.; however, this is probably explained by the lower fructose
dose used in our protocol. Fructose has long been known to cause
an acute increase in uric acid concentration when given in large
doses over a short period, i.e., with intravenous administration
or large oral fructose loads (42). Under such conditions, the
higher activity of fructokinase in regard to that of ALDOB causes
a transient intracellular accumulation of fructose-1-phosphate,
together with ATP depletion and purine catabolism (43).
However, ingestion of mixed meals containing fructose, or lower
fructose loads, does not seem to elicit such an acute increase in
uric acid concentration in normal subjects (44). Our observation
that hHFI subjects had a modest yet significant increase in
postprandial uric acid concentrations in response to such a low
fructose load suggests that their reduced levels of ALDOB make
them more sensitive to fructose-induced transient ATP depletion.
Since renal proximal tubular cells metabolize fructose, and
since acute proximal tubule dysfunction is a hallmark of acute
and chronic reactions to fructose in patients with HFI, we
also considered the possibility that fructose administration may
acutely affect renal processes. We did not, however, observe
any urinary indexes of tubular dysfunction (Fe-Na, Fe-Urea,
pH, and glucose). An exploratory analysis of plasma and urine
amino acid concentrations was included to search for possible
indications of altered tubular amino acid reabsorption since this is
a prominent effect of fructose in ALDOB-deficient HFI patients.
However, hHFI subjects had no increase in urine amino acid
excretion after fructose loading. A careful analysis nonetheless
revealed a slight increase in the baseline glycine concentration
and a trend for an increase in arginine concentration, together
with an increased urea:Crt ratio. This, together with low Crt,
made us suspect that hHFI subjects may have some defect in
Cr metabolism. Endogenous Cr is synthesized from arginine
and glycine in the liver, which is converted to GAA via
the successive action of arginine:glycine amidinotransferase
and guanidinoacetate methyltransferase (45–47). To further
investigate Cr biosynthesis, Cr and its precursor GAA were
measured in plasma and urine. However, there was no significant
difference between the hHFI and control groups. Furthermore,
there are no reports in the literature of a defect in Cr synthesis
associated with HFI. We also reassessed the data of HFI patients
followed at our clinics and did not find any biochemical evidence
for such a defect. We further considered the possibility that it
may be explained by major differences in the diet compositions
of the hHFI and control subjects. This appears unlikely, however,
since all participants were on the same controlled, low-fructose
diet over the week preceding the experiments. Furthermore, we
recontacted all hHFI participants a posteriori, and obtained a
3-d dietary diary from 7 of them. Analysis of these diaries
indicated that fructose accounted for 6.31% ± 2.0% of their total
energy intake, i.e., close to the average consumption of a normal
population (48). We can therefore discard the hypothesis that
the difference was because of the hHFI subjects spontaneously
consuming a low-fructose diet. In the absence of additional
metabolic alterations, we therefore conclude that these small
alterations may be fortuitous.
Our study has some limitations which must be pointed out.
First, we used a fructose-containing mixed test meal challenge
instead of a large pure fructose load, and cannot discard the
hypothesis that a larger load of fructose would have been required
to exceed the catalytic activity of the remaining ALDOB in
heterozygotes. This choice was, however, made in order to meet
the recommendation of a recent NIH panel position paper to study
the effects of fructose relevant to real nutrition, i.e., together with
other macronutrients and equimolar amounts of glucose (39).
Second, our study evaluated only the acute effect of a single
fructose load in subjects who had been on a low-fructose diet
for the previous 7 d. This design had been chosen to search
for signs of altered fructose metabolism (i.e., slower fructose
oxidation, uric acid production), but may not be optimal to search
for increased sensitivity to the long-term metabolic effects of
fructose. An experimental design including an exposure to dietary
fructose over several daysmay be needed to document differences
between hHFI and control subjects.
In conclusion, hHFI subjects had no major alteration of
postprandial glucose homeostasis or of fructose metabolism after
ingestion of a fructose-containing meal. They did, however, have
a slight but significant increase in uric acid concentrations after
ingestion of a single fructose-containing mixed meal, which
suggests that their reduced ALDOB expression is associated with
subtle metabolic changes.
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